Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 161 participants.

Also called NCT01892020

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 161 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01892020
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01892020. Randomized; no masking; primary purpose treatment. Start 2013-06 (registry gives no type); primary completion 2014-05 (actual). Results posted on 2015-07-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
biphasic insulin aspart 50
Intervention (Drug)
biphasic human insulin 50
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01892020
Content hash
88b35ebe899f3198a30f6e5856038615a2336c8deb4b4fc91cac9b8f78de99c4